Full-Time
Updated on 8/22/2026
Markets real-time CGM devices and analytics
CA$170.3k - CA$283.9k/yr
Remote in Canada
Remote
Remote home office; 5–15% travel required. Hybrid work may be available near a Dexcom site.
Bachelor's
See people who can refer or advise you
Dexcom develops continuous glucose monitoring systems to help people manage diabetes. Its core Dexcom G6 uses a wearable sensor and transmitter to stream real-time glucose data to a display or smartphone, with factory calibration and no routine finger-prick calibrations. It differentiates itself with a complete ecosystem including analytics software like Dexcom CLARITY and subscription services that share data with clinicians and caregivers. Its goal is to improve quality of life by providing accurate, easy-to-use glucose monitoring and actionable insights.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
1999
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Professional Development Budget
Remote Work Options
Flexible Work Hours
Tuition Reimbursement
DexCom shares have surged 52.5% over the past three months, significantly outpacing the broader market's 2.4% gain and its medical sector's 10.4% rise. The rally followed strong second-quarter results. Revenue increased 13.1% year-over-year to $1.31 billion, whilst adjusted earnings of 70 cents per share beat consensus estimates of 61 cents. US revenues rose 11% to $933.4 million, and international revenues jumped 19% to $375 million. Margin expansion bolstered the growth story. Adjusted gross margin reached 64.1%, up 400 basis points year-over-year, whilst adjusted operating margin improved 590 basis points to 25.1%. DexCom now trades at 30.7 times forward earnings, above its sub-industry average of 27.3 times. The premium valuation means future gains will depend on sustained earnings delivery and market access expansion rather than multiple expansion.
DexCom reported 12% organic revenue growth in Q2 2026, driven by record customer acquisition and market share gains. The company raised full-year guidance by over 50 basis points despite a projected $15 million foreign exchange headwind. The CONNECT trial showed 1.6% A1C improvement for non-insulin type 2 diabetes users, supporting reimbursement expansion. DexCom secured coverage for over 7 million non-insulin patients across the four largest US commercial pharmacy benefit managers. The company acquired Nutrisense to integrate nutrition-focused AI insights into its product ecosystem. DexCom executed $600 million of its $1 billion share repurchase programme during the quarter. Gross margins improved 400 basis points year-over-year to 64.1%, driven by manufacturing efficiencies. The company targets converting approximately 50% of US customers to its G7 15-day system by year-end 2026.
DexCom Inc reported strong second-quarter 2026 results, with worldwide revenue of $1.31 billion, up 13% year-over-year. US revenue reached $933 million (up 11%) whilst international revenue grew 19% to $375 million. Gross profit margin improved significantly to 64.1%, up from 60.1% in Q2 2025, driven by manufacturing efficiencies and the transition to the G7 15-day system. Operating income rose to $328.3 million, representing 25.1% of revenue. Net income increased 46% year-over-year to $269.1 million, or $0.70 per share. The company generated over $600 million in free cash flow in the first half of 2026, more than double the prior year period. DexCom raised its full-year 2026 revenue guidance to $5.18 billion to $5.25 billion, representing 11%-13% growth. The company also increased gross margin guidance to approximately 64% and operating margin guidance to 23.5%-24%.
Dexcom raised its full-year revenue forecast on Thursday, driven by strong demand for its continuous glucose monitors. The medical device maker now expects annual revenue between $5.18 billion and $5.25 billion, up from its previous range of $5.16 billion to $5.25 billion. The company reported second-quarter revenue of $1.31 billion, a 13% increase year-over-year, beating analyst estimates of $1.29 billion. Adjusted profit reached 70 cents per share, surpassing the 61-cent estimate. Rising awareness of diabetes care, improved insurance coverage, and consumer preference for finger-prick-free technology have boosted demand for continuous glucose monitors. Dexcom competes in this market alongside Medtronic and Abbott Laboratories. Following the announcement, Dexcom's shares rose over 4% in extended trading.
SEB Asset Management AB purchased a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) in the first quarter, HoldingsChannel reports. The firm purchased 377,064 shares of the medical device company’s stock, valued at approximately $23,680,000. A number of other hedge funds have also modified their holdings of the company. Reflection Asset Management acquired a […]